Poxel taking two shots at NASH as pharma waits on FDA's OCA ...

Intercept’s obeticholic acid (OCA) is under review in the potentially lucrative fatty liver disease non-alcoholic steatohepatitis (NA

Novo bolsters R&D pipeline with RNAi therapies from Dicerna

Novo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to discover and develop RNA-blocking therapies for diseases such as NASH and ty

Genfit announces data from algorithm-based NASH test

The pharma company Genfit has announced supportive data from a study involving a non-invasive algorithm driven blood test for the fatty liver disease known as NASH, a potential replacement

Novo Nordisk buys rights to NASH drug from Japan's UBE

Novo Nordisk has acquired rights to a preclinical drug that could be used to treat non-alcoholic steatohepatitis (NASH), the fatty liver disease that could generate billions of dollars for

Novartis takes $80M punt on early-stage NASH drug from Plian...

Pfizer inks deal with Ionis and Akcea for potential blockbus...

Pfizer has signed a deal with Ionis’ affiliate Akcea Therapeutics, to develop a potential blockbuster antisense therapy to treat patients with certain cardiovascular and metabolic diseases